Completed PHASE3 INTERVENTIONAL 2-arm NCT03170271

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. (ANDHI)

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients With Severe Asthma Uncontrolled on Standard of Care Treatment

Sponsor: AstraZeneca

Conditions Asthma

Interventions Benralizumab (Medi-563) Placebo

Updated 22 times since 2017 Last updated: Oct 20, 2021 Started: Jul 7, 2017 Primary completion: Sep 25, 2019 Completion: Oct 21, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Asthma and is currently completed. AstraZeneca leads this study, which shows 22 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

22 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed

▶ Show 17 earlier versions

Oct 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Jul 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE3
May 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE3
Nov 2019 — May 2020 [monthly]

Active Not Recruiting PHASE3
Jul 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2018 — Jul 2019 [monthly]

Recruiting PHASE3
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE3
Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE3
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Jan 2018 — Apr 2018 [monthly]

Recruiting PHASE3
Dec 2017 — Jan 2018 [monthly]

Recruiting PHASE3
Nov 2017 — Dec 2017 [monthly]

Recruiting PHASE3
Oct 2017 — Nov 2017 [monthly]

Recruiting PHASE3
Sep 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Aug 2017 — Sep 2017 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jul 2017 — Aug 2017 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus N, Denmark , Abingdon, United States , Ajax, Canada , Albany, United States , Albuquerque, United States , Amersfoort, Netherlands , Anderson, United States , Ann Arbor, United States , Aurora, United States , Badalona(Barcelona), Spain and 188 more locations